Breaking News, Collaborations & Alliances

APO-T, LinXis in ADC Alliance

Gains license to antibodies and linker technology

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

LinXis has granted APO-T an exclusive worldwide license for the development and commercialization of fully-human antibody-drug-conjugates using APO-T’s MAGE-HLA targeted antibodies and LX linker technology. In return, LinXis will receive milestone payments and royalties.   “We are excited to license this program from LinXis, a company known for the development of innovative linker technology for the conjugation of cytotoxic drugs to antibodies. We are convinced by the sound scientific data LinXi...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters